You are here

FAST-DENV™: A Point-of-Care Dengue Serodiagnostic

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-20-P-0032
Agency Tracking Number: A192-124-0253
Amount: $111,499.14
Phase: Phase I
Program: SBIR
Solicitation Topic Code: A19-124
Solicitation Number: 19.2
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2019-10-30
Award End Date (Contract End Date): 2020-08-27
Small Business Information
301 1st Street SW Suite 200
Roanoke, VA 24011
United States
DUNS: 627132913
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Nathaniel Talley
 Principal Investigator
 (434) 972-9951
Business Contact
 Michael Pruzan
Phone: (540) 769-8430
Research Institution

Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen in the world with nearly 400 million infections occurring annually. The infection risk for deployed troops has increased with the global incidence of dengue, leading to a loss in mission capabilities as soldiers are hospitalized, treated, and evacuated. DengVaxia, a recombinant live-attenuated tetravalent vaccine, is licensed and available in 20 countries. However, Phase 3 clinical trials indicated an increased risk of dengue complications if the vaccine was administered to those that had no prior dengue infection. Current methods to determine serostatus include the plaque reduction neutralization test or ELISA, though these tests are currently not available at the point-of-care, require skilled personnel, cold-chain transport, and are not suitable for large-scale vaccination programs. Thus, there is a critical need for a sensitive, high throughput technology to rapidly determine DENV serostatus and inform vaccination strategies. To meet this need, Luna Innovations will develop with FAST-DENV technology, featuring automated microfluidic point-of-care ELISAs that will enable rapid (=15 minutes) detection of antibodies indicating prior infection from a fingerprick blood sample (=15 µL). During Phase I, ELISAs will be developed and demonstrated to be highly sensitive (=90%) and specific (=90%) with clinical sample panels.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government